Puerarin: A Potential Therapeutic for Colon Adenocarcinoma (COAD) Patients Suffering From SARS-CoV-2 Infection

Frontiers in Pharmacology

Qingxue Meng¹  Xueliang Wu²  Jun Xue²  Weizheng Liang²  Yue Yao³  Xiushen Li⁶  Hao Wang⁶ 

[1] Central Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China;Department of General Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China;Department of Internal Medicine of Traditional Chinese Medicine, The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China;Department of Obstetrics and Gynecology, Shenzhen University General Hospital, Shenzhen, China;Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, China;Shenzhen Key Laboratory, Shenzhen University General Hospital, Shenzhen, China;

关键词: puerarin;    COVID-19;    COAD;    comorbidity;    network pharmacology;    bioinformatics;   

DOI  :  10.3389/fphar.2022.921517

来源: DOAJ

【 摘 要 】

Patients with colonic adenocarcinoma (COAD) are at relatively high risk of SARS-CoV-2 infection. However, there is a lack of medical strategies to treat COVID-19/COAD comorbidity. Puerarin, a natural product, is a known antiviral, antitumor, and immunomodulatory effect. Therefore, we hypothesised that puerarin could be used to treat COVID-19/COAD patients. Based on network pharmacology and bioinformatics analysis, the potential targets and pharmacological mechanisms of puerarin in COVID-19/COAD were identified. By intersecting therapeutic target genes for puerarin, COVID-19-related genes and COAD-related genes, 42 target genes of puerarin that could potentially treat COVID-19/COAD comorbidity were obtained. By using the 42 potential target genes to construct the protein-protein interaction (PPI) network, we obtained five core target genes, namely RELA, BCL2, JUN, FOS, and MAPK1. The results of bioinformatics analysis revealed that puerarin could be able to treat COVID-19/COAD comorbidity through apoptosis, antiviral, antioxidant, NF-κB signaling pathway, MAPK signaling pathway, IL-17 signaling pathway, TNF signaling pathway, and HIF-1 signaling pathway etc. This study found that puerarin has the potential to treat COVID-19/COAD patients and that the therapeutic target genes obtained in the study may provide clues for the treatment of COVID19/COAD comorbidity.

【 授权许可】

Unknown